Therapeutic pharmaceutical composition for bone and soft tissue tumors
AssigneeSurv BioPharma Inc.
InventorsKen-ichiro Kosai, Satoshi Nagano, Toshitaka Futagawa
Life of this patent
Estimating the term…
Abstract
A method for treating a bone and soft tissue tumor, including administering a conditionally replicating adenovirus having a E1A gene under expression control of a Survivin promoter, to a subject in need thereof. A conditionally replicating adenovirus including a E1A gene under expression control of a Survivin promoter and the conditionally replicating adenovirus is not defective in a E3 region.
Claims18
A pharmaceutical composition for treating a bone and soft tissue tumor, comprising:
- a conditionally replicating adenovirus having an ELA gene under expression control of a Survivin promoter;
- and
- a pharmacologically acceptable carrier,
- wherein the conditionally replicating adenovirus is not defective in an E3 region, and
- wherein an E1B region of the conditionally replicating adenovirus is E1BΔ55K.
A pharmaceutical composition for treating a bone and soft tissue tumor, comprising:
- a conditionally replicating adenovirus having an E1A gene under expression control of a Survivin promoter;
- and
- a pharmacologically acceptable carrier,
- wherein the conditionally replicating adenovirus is not defective in an E3 region, and
- wherein an E1B region is E1BΔ55K and is controlled by a CMV promoter.
A conditionally replicating adenovirus having the ELA gene under expression control of a Survivin promoter, wherein the conditionally replicating adenovirus is not defective in an E3 region, and
- wherein an E1B region is E1BΔ55K and is controlled by a CMV promoter.
Dependencies are inferred from the claim text.